Literature DB >> 8195148

Human hepatitis virus X gene encodes a regulatory domain that represses transactivation of X protein.

S Murakami1, J H Cheong, S Kaneko.   

Abstract

The human hepatitis B virus (HBV) X gene seems to be essential for establishment of viral infection, and the X gene product, HBx, transactivates virus and host genes through a wide variety of cis-elements, whereas regulation of HBx has not been fully understood. We found that transactivation-negative HBx mutants truncated at the C-terminal portion specifically repressed the HBx transactivation in trans. The ability to trans-repress the HBx transactivation is confined to the N-terminal third of HBx. Transactivation-positive constructs of HBx were divided into two groups by their sensitivity to trans-repression due to the presence of the N-terminal third. Thus the regulatory domain, the N-terminal third, is separated from the transacting domain and responsible for the negative regulations, the trans-repression and sensitivity to X trans-repression. A possible direct association between the HBx regulatory domains was tested by far-Western blotting using purified fused forms of HBx proteins. The regulatory domain was found to associate preferentially with the full HBx or the regulatory domain, but not with the transacting domain. Taken together, it is possible that HBx has a self-regulatory mechanism that avoids excessive HBx transactivation and is important for regulation of X gene expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195148

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Different regions of hepatitis B virus X protein are required for enhancement of bZip-mediated transactivation versus transrepression.

Authors:  S Barnabas; O M Andrisani
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Hepatitis C virus envelope proteins bind lactoferrin.

Authors:  M Yi; S Kaneko; D Y Yu; S Murakami
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  The enigmatic X gene of hepatitis B virus.

Authors:  Michael J Bouchard; Robert J Schneider
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and Upregulate Hepatitis B Virus Replication from cccDNA to Virion in an HBx-Dependent Manner.

Authors:  Umar Saeed; Jumi Kim; Zahra Zahid Piracha; Hyeonjoong Kwon; Jaesung Jung; Yong-Joon Chwae; Sun Park; Ho-Joon Shin; Kyongmin Kim
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

5.  XAP2, a novel hepatitis B virus X-associated protein that inhibits X transactivation.

Authors:  N Kuzhandaivelu; Y S Cong; C Inouye; W M Yang; E Seto
Journal:  Nucleic Acids Res       Date:  1996-12-01       Impact factor: 16.971

6.  X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo.

Authors:  Z Zhang; N Torii; Z Hu; J Jacob; T J Liang
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

7.  Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication.

Authors:  Amanda J Hodgson; Joseph M Hyser; Victor V Keasler; Yong Cang; Betty L Slagle
Journal:  Virology       Date:  2012-02-17       Impact factor: 3.616

8.  A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function.

Authors:  V Kumar; N Jayasuryan; R Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 9.  Hepatitis B Virus X and Regulation of Viral Gene Expression.

Authors:  Betty L Slagle; Michael J Bouchard
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-08       Impact factor: 6.915

10.  Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation.

Authors:  R Truant; J Antunovic; J Greenblatt; C Prives; J A Cromlish
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.